BOLT

Bolt Biotherapeutics Inc

5.91

Nov 12 • 3:59 PM ET -0.35 (-5.59%)

5.91

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Today, 5:16 PMBolt Biotherapeutics reports third-quarter net loss of $4.4 million, or $2.25 per share

Peers: STRO HOWL PYXS CTMX XLO CRBP ZYME STTK ALXO CUE

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	11.39M
Enterprise Value	15.21M
Income	-28.74M
Sales	4.70M
Book/sh	6.56
Cash/sh	9.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	Feb 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	2.42
P/B	0.90
P/C	0.64
P/FCF	-
EV/EBITDA	-
EV/Sales	3.24
Quick Ratio	2.61
Current Ratio	2.61
Debt/Eq	1.71
LT Debt/Eq	1.47
Option/Short	No / Yes

EPS (ttm)	-16.44
EPS next Y	-20.19
EPS next Q	-3.69
EPS this Y	-2.35%
EPS next Y	-10.51%
EPS next 5Y	-19.99%
EPS past 3/5Y	27.67% 11.84%
Sales past 3/5Y	10.33% 101.61%
EPS Y/Y TTM	37.93%
Sales Y/Y TTM	12.79%
EPS Q/Q	-2.29%
Sales Q/Q	-99.72%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-34.94% -99.00%

Insider Own	14.93%
Insider Trans	4.57%
Inst Own	39.39%
Inst Trans	-
ROA	-49.62%
ROE	-111.65%
ROIC	-92.19%
Gross Margin	80.45%
Oper. Margin	-605.85%
Profit Margin	-611.47%
SMA20	1.36%
SMA50	28.98%
SMA200	31.40%
Trades

Shs Outstand	1.93M
Shs Float	1.64M
Short Float	2.89%
Short Ratio	0.19
Short Interest	0.05M
52W High	7.78 -24.04%
52W Low	3.10 90.65%
Volatility	5.93% 9.13%
ATR (14)	0.48
RSI (14)	55.99
Beta	0.82
Rel Volume	0.71
Avg Volume	250.16K
Volume	177,678

Perf Week	-7.37%
Perf Month	48.49%
Perf Quarter	76.42%
Perf Half Y	18.20%
Perf YTD	8.08%
Perf Year	26.01%
Perf 3Y	-69.54%
Perf 5Y	-97.18%
Perf 10Y	-
Recom	1.67
Target Price	48.50
Prev Close	6.26
Price	5.91
Change %	-5.59%

Consensus

Buy

Avg. Price Target

$48.50

Implied Upside

+720.6%

Analysts6incl. previous ratings

Rating Distribution5 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 29, 2026	Initiated	RRodman & Renshaw	Buy	$22	+272.3%
Oct 20, 2025	Resumed	HH.C. Wainwright	Buy	$7	+18.4%
Jan 06, 2022	Downgrade	MMorgan Stanley	Overweight → Equal-Weight
Mar 02, 2021	Initiated	SSVB Leerink	Outperform	$36	+509.1%
Mar 02, 2021	Initiated	SStifel	Buy	$40	+576.8%
Mar 02, 2021	Initiated	MMorgan Stanley	Overweight	$45	+661.4%
Mar 02, 2021	Initiated	GGuggenheim	Buy	$42	+610.7%

Today 04:56PM	Bolt Biotherapeutics, Inc.: Q3 Earnings Snapshot (Associated Press) -5.59%
04:05PM	Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-26 08:00AM	Bolt Biotherapeutics to Participate in Upcoming Conferences (GlobeNewswire) +5.29%
Oct-28-26 09:27AM	Lilly shuffles business structure; Novartis writes off part of Avidity deal (BioPharma Dive)
Oct-23-26 09:08AM	Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications (GlobeNewswire) +49.64%
04:41PM	Loading…
Aug-11-26 04:41PM	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot (Associated Press) -13.32%
04:05PM	Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 04:18PM	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot (Associated Press)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-26 04:51PM	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 08:00AM	Bolt Biotherapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Nov-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:21PM	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Loading…
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -9.68%
Oct-01-25 04:05PM	Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 (GlobeNewswire) +6.39% -12.37%
Aug-14-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.33%
04:24PM	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-25 08:00AM	ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
May-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.70%
05:10PM	Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:28PM	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates (GlobeNewswire)
Apr-30-25 04:05PM	Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 (GlobeNewswire)
01:00PM	Loading…
Apr-25-25 01:00PM	Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 (GlobeNewswire)
Mar-25-25 04:30PM	Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 (GlobeNewswire)
Mar-24-25 04:37PM	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:20PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 04:05PM	Bolt Biotherapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-11-25 04:05PM	Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. (GlobeNewswire)
Nov-12-24 05:35PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-24 10:00AM	Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting (GlobeNewswire)
Sep-04-24 04:05PM	Bolt Biotherapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Aug-28-24 07:00AM	Bolt Biotherapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-24-24 06:13AM	The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows (InvestorPlace)
May-15-24 03:00PM	Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ... (GuruFocus.com) -37.12%
01:34PM	Top Midday Decliners (MT Newswires)
08:05AM	Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate (BioPharma Dive)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-14-24 10:54PM	BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team (GlobeNewswire)
Mar-21-24 10:53PM	BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-24 07:00AM	Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-05-23 07:00AM	Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu (GlobeNewswire)
Nov-09-23 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 07:00AM	Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-23-23 10:30AM	Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress (GlobeNewswire) -7.80%
Oct-18-23 07:00AM	Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting (GlobeNewswire)
Oct-17-23 07:00AM	Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers (GlobeNewswire)
Oct-16-23 07:00AM	Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 (GlobeNewswire) +6.25%
Sep-28-23 07:00AM	Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers (GlobeNewswire)
Sep-12-23 08:05AM	Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042 (GlobeNewswire)
Sep-05-23 04:15PM	Bolt Biotherapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-09-23 06:10AM	Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.)
Aug-07-23 04:10PM	Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer (GlobeNewswire)
Jul-31-23 05:27PM	Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-13-23 11:22AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-30-23 08:00AM	BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases (PR Newswire) -6.56%
May-25-23 05:05PM	Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 04:05PM	Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +12.50%
Apr-26-23 10:00AM	Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-11-23 07:41AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year (Simply Wall St.)
Mar-30-23 01:16PM	Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies (Benzinga)
Mar-29-23 04:15PM	Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies (GlobeNewswire)
Mar-14-23 04:30PM	Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting (GlobeNewswire) +7.86%
Feb-28-23 08:00AM	Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Bolt Biotherapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-04-23 09:31AM	Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation (Simply Wall St.)
Dec-14-22 04:43PM	Bolt Biotherapeutics Appoints Laura Berner to Board of Directors (GlobeNewswire)
Nov-10-22 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 08:00AM	Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting (GlobeNewswire)
Nov-02-22 07:20AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year (Simply Wall St.)
Nov-01-22 10:01AM	Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference (GlobeNewswire)
Sep-09-22 12:08PM	16 Best Penny Stocks to Buy Now (Insider Monkey)
Aug-31-22 07:30AM	Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-22 12:23PM	Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead? (Zacks)
12:02PM	J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli (Zacks)
Aug-10-22 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +10.53% -6.35%
Jul-22-22 08:44AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -5.75%
Jun-10-22 07:21AM	Zacks.com featured highlights include Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery (Zacks) -6.57%
May-27-22 08:00AM	Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 (GlobeNewswire)
May-26-22 06:52AM	The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable (Simply Wall St.)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 04:05PM	Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +5.41%
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks) -10.30%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coastlands Capital LP	10% Owner	Nov 09 '26	Buy	6.38	50,000	319,000	462,416	Nov 10 02:57 PM
Yonehiro Grant	Chief Operating Officer	Sep 18 '26	Sale	3.24	6,850	22,169	17,269	Sep 21 06:05 PM
Yonehiro Grant	Chief Operating Officer	Sep 17 '26	Sale	3.32	4,909	16,290	24,119	Sep 21 06:05 PM
Yonehiro Grant	Chief Operating Officer	Sep 16 '26	Sale	3.77	1,417	5,348	29,028	Sep 21 06:05 PM
Nemec Sarah	Senior VP, Finance and PAO	Jun 05 '26	Buy	3.88	509	1,973	1,924	Sep 21 06:04 PM
Nemec Sarah	Senior VP, Finance and PAO	Sep 18 '26	Sale	3.24	4,077	13,195	17,082	Sep 21 06:04 PM
Nemec Sarah	Senior VP, Finance and PAO	Sep 17 '26	Sale	3.32	2,922	9,696	21,159	Sep 21 06:04 PM
Nemec Sarah	Senior VP, Finance and PAO	Sep 16 '26	Sale	3.77	843	3,181	24,081	Sep 21 06:04 PM
Quinn William P.	President, CEO and CFO	Jun 05 '26	Buy	3.88	637	2,469	2,950	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Sep 18 '26	Sale	3.24	9,132	29,555	25,384	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Sep 17 '26	Sale	3.32	6,545	21,718	34,516	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Sep 16 '26	Sale	3.77	1,889	7,129	41,061	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Dec 05 '25	Buy	4.61	125	576	2,313	Feb 04 04:32 PM
Nemec Sarah	Senior VP, Finance and PAO	Dec 05 '25	Buy	4.61	125	576	1,415	Feb 04 04:32 PM

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Co-Founder & DirectorDr. Sheila K. Gujrathi M.D.

Founder & Strategic Scientific AdvisorDr. Miguel Sanjuan Ph.D.

Chief Scientific OfficerDr. Ryan Sullivan Ph.D.

Vice President of Corporate DevelopmentChristina Trout

Chief Medical OfficerMr. Hector Ortega M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

BOLT

Bolt Biotherapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.